Literature DB >> 8849584

Mechanical and neuroendocrine regulation of the endocrine heart.

A J de Bold1, B G Bruneau, M L Kuroski de Bold.   

Abstract

The cardiac natriuretic peptides (NP) -- atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) -- are polypeptide hormones produced by cardiocytes in the atria of mammals. ANF and BNP are continuously released from the heart, but appropriate mechanical or neuroendocrine stimuli increase their rate of release with or without a concomitant increase in synthesis. The results of our investigations lead us to propose that the endocrine response of the heart to pressure or volume load varies in relation to whether the challenge is acute, subacute or chronic. The acute response to stretch is based on a phenomenon referred to as "stretch-secretion coupling" which results in enhanced secretion of NP stored in the atria. NP release following stretch is made at the expense of a depletable NP pool with no apparent effect on synthesis. The stimulation of NP production that is seen during mineralcorticoid escape is referred to as "subacute" and is characterized by stimulation of atrial ANF and BNP gene transcription secondary to volume overload in which plasma ANF, but not plasma BNP, is significantly elevated. With chronic stimulation, as seen in DOCA-salt treatment at the hypertensive stage, activation of the cardiac fetal program in ventricle is seen together with a stimulation of ANF and BNP production in both atria and ventricles. However, the activation of NP gene expression in the atria is not necessarily associated with fetal isogene expression even though the ventricular hypertrophic process is characterized by the expression of fetal isogenes, including ANF and BNP, that are normally expressed in the fetal ventricle. It seems likely that the acute stimulation of NP release is based on an electromechanical coupling. However, protracted stimulation of release is seen in situations in which profound neuroendocrine changes have taken place, thus suggesting that the primary stimulus for chronically enhanced NP gene expression and NP release is based on changes in the hormonal environment of the atrial cardiocyte. It is concluded that the endocrine heart responds to changes in hemodynamic load with specific changes in translational, post-translational and storage processes for ANF and BNP following acute or chronic stimulation. As a result, plasma levels of ANF and BNP may be used as indicators of the degree of atrial hemodynamic overload and ventricular hypertrophy, respectively. It may be advanced that the endocrine heart differentiates and responds to different hemodynamic challenges in either acute or chronic conditions with specific changes in transcription, translation, post-translational processing, storage, and release of ANF and BNP. We propose that this differentiation is part of the reason for the heart to produce two hormones with similar spectra of activity. This paradigm warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8849584

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  44 in total

Review 1.  Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure.

Authors:  Chaitanya Madamanchi; Hassan Alhosaini; Arihiro Sumida; Marschall S Runge
Journal:  Int J Cardiol       Date:  2014-08-09       Impact factor: 4.164

2.  The exocrine pancreas is an extracardiac source of atrial natriuretic peptide.

Authors:  Ana C Najenson; Mariana Bianchi; Ana P Courreges; Myrian R Rodriguez; Víctor H Casco; Marcelo S Vatta; Liliana G Bianciotti
Journal:  Pflugers Arch       Date:  2019-01-08       Impact factor: 3.657

Review 3.  The paradox of low BNP levels in obesity.

Authors:  Aldo Clerico; Alberto Giannoni; Simona Vittorini; Michele Emdin
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

4.  Electrolyte and hemodynamic changes following percutaneous left atrial appendage ligation with the LARIAT device.

Authors:  Ryan Maybrook; Jayasree Pillarisetti; Vivek Yarlagadda; Sampath Gunda; Arun Raghav Mahankali Sridhar; Brent Deibert; Muhammad R Afzal; Madhu Reddy; Donita Atkins; Matthew Earnest; Ryan Ferrell; Jayant Nath; Arun Kanmanthareddy; Sudharani Bommana; Rajasingh Johnson; Sandeep Reddy Koripalli; Buddhadeb Dawn; Dhanunjaya Lakkireddy
Journal:  J Interv Card Electrophysiol       Date:  2015-05-09       Impact factor: 1.900

5.  Catheter ablation of atrial fibrillation and outcomes in heart failure patients: seeking the treasure in the CASTLE.

Authors:  Stanley Nattel
Journal:  Cardiovasc Res       Date:  2018-06-01       Impact factor: 10.787

6.  Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population.

Authors:  S Jeson Sangaralingham; Paul M McKie; Tomoko Ichiki; Christopher G Scott; Denise M Heublein; Horng H Chen; Kent R Bailey; Margaret M Redfield; Richard J Rodeheffer; John C Burnett
Journal:  Hypertension       Date:  2015-04-20       Impact factor: 10.190

Review 7.  Brain natriuretic peptide and optimal management of heart failure.

Authors:  Nan Li; Jian-An Wang
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

8.  Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study.

Authors:  Raquel Cortés; Miguel Rivera; Antonio Salvador; Vicente Bertomeu; Fernando García de Burgos; Esther Roselló-Lletí; Manuel Portolés; Rafael Payá; Luis Martínez-Dolz; Vicente Climent
Journal:  Heart       Date:  2007-05-08       Impact factor: 5.994

9.  Norepinephrine-induced cardiac hypertrophy and fibrosis are not due to mast cell degranulation.

Authors:  Wilfried Briest; Beate Rassler; Alexander Deten; Heinz-Gerd Zimmer
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

Review 10.  B-type natriuretic peptide: physiologic role and assay characteristics.

Authors:  Hassan M E Azzazy; Robert H Christenson
Journal:  Heart Fail Rev       Date:  2003-10       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.